As of May 22
| +0.20 / +1.16%|
The 8 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 20.00, with a high estimate of 26.00 and a low estimate of 6.00. The median estimate represents a +14.61% increase from the last price of 17.45.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.